Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial
Daniel John Pollard,Alan Brennan,Simon Dixon,Norman Waugh,Jackie Elliott,Simon Heller,Ellen Lee,Michael Campbell,Hasan Basarir,David White,Stephanie Amiel,Mark Evans,Fiona Green,Peter Hammond,Alan Jaap,Brian Kennon,Robert Lindsay,Peter Manselljane Baillie,Anita Beckwith,Helen Brown,Karen Callaby,Katy Davenport,Sarah Donald,Leila Faghahati,Sara Hartnell,Allison Housden,Kalbir Kaur Pabla,Nicola Croxon,Sheena Macdonald,Muna Mohammed,Vicky Steel,Katy Valentine,Pamela Young,Ann Boal,Patsy Clerkin,Lynn Doran,Joanne Flynn,Emma Gibb,Hilary Peddie,Bernie Quinn,Helen Rogers,Janice Shephard,Janet Carling,Ann Collins,Laura Dinning,Christine Hare,Joyce Lodge,Sutapa Ray,Debora Brown,Jenny Farmer,Alison Cox,Chris Cheyette,Pratik Choudhary,Linda East,June Ellul,Katherine Hunt,Kimberley Shaw,Ben Stothard,Lucy Diamond,Lindsay Aniello,Debbie Anderson,Kathy Cockerell,Vida Heaney,Alison Hutchison,Nicola Zammitt,Gayna Babington,Gail Bird,Janet Evans,Tasso Gazis,Nicola Maude,Karen Nunnick,Dawn Spick,Laura Fenn,Carla Gianfrancesco,Valerie Gordon,Linda Greaves,Susan Hudson,Valerie Naylor,Chloe Nisbet,Carolin Taylor,Karen Towse,Candice Ward,Cindy Cooper,Gemma Hackney,Diana Papaioannou,Emma Whatley,Mike Bradburn,Munya Dimairo,Nina Hallowell,Jackie Kirkham,Julia Lawton,David Rankin,Katharine Barnard,Timothy Chater,Kirsty Pemberton,Fiona Allsop,Lucy Carr,Pamela Royle,Gill Thompson,Sharon Walker,Pauline Cowling,Henry Smithson
DOI: https://doi.org/10.1136/bmjopen-2017-016766
IF: 3.006
2019-10-03
BMJ Open
Abstract:Objectives To assess the long-term cost-effectiveness of insulin pumps and Dose Adjustment for Normal Eating (pumps+DAFNE) compared with multiple daily insulin injections and DAFNE (MDI+DAFNE) for adults with type 1 diabetes mellitus (T1DM) in the UK. Methods We undertook a cost–utility analysis using the Sheffield Type 1 Diabetes Policy Model and data from the Relative Effectiveness of Pumps over Structured Education (REPOSE) trial to estimate the lifetime incidence of diabetic complications, intervention-based resource use and associated effects on costs and quality-adjusted life years (QALYs). All economic analyses took a National Health Service and personal social services perspective and discounted costs and QALYs at 3.5% per annum. A probabilistic sensitivity analysis was performed on the base case. Further uncertainties in the cost of pumps and the evidence used to inform the model were explored using scenario analyses. Setting Eight diabetes centres in England and Scotland. Participants Adults with T1DM who were eligible to receive a structured education course and did not have a strong clinical indication or a preference for a pump. Intervention Pumps+DAFNE. Comparator MDI+DAFNE. Main outcome measures Incremental costs, incremental QALYs gained and incremental cost-effectiveness ratios (ICERs). Results Compared with MDI+DAFNE, pumps+DAFNE was associated with an incremental discounted lifetime cost of +£18 853 (95% CI £6175 to £31 645) and a gain in discounted lifetime QALYs of +0.13 (95% CI –0.70 to +0.96). The base case mean ICER was £142 195 per QALY gained. The probability of pump+DAFNE being cost-effective using a cost-effectiveness threshold of £20 000 per QALY gained was 14.0%. All scenario and subgroup analyses examined indicated that the ICER was unlikely to fall below £30 000 per QALY gained. Conclusions Our analysis of the REPOSE data suggests that routine use of pumps in adults without an immediate clinical need for a pump, as identified by National Institute for Health and Care Excellence, would not be cost-effective. Trial registration number ISRCTN61215213 .
medicine, general & internal